ImmuPharma PLC has spotlighted early-stage research from the University of Murcia exploring its lead drug candidate, the P140 peptide, as a possible treatment for glioblastoma, a highly aggressive brain cancer. While the company primarily focuses on developing P140 for autoimmune diseases, this new research suggests an additional application for the drug. ImmuPharma has been monitoring this research since 2024 and remains committed to advancing P140 as its lead asset. The glioblastoma findings support the company's broader scientific rationale but do not change its core strategy.
Greg Abel, Warren Buffett's successor at Berkshire Hathaway, reduced the company's investment in Bank of America by $1.7 billion. At the same time, he increased the stake in Delta Air Lines by $1.6 billion. This shift in portfolio allocation highligh...
Xaman Wallet, a key app for the XRP Ledger ecosystem, has eliminated its 0.09 XRP minimum trading fee to encourage more liquidity and enable smaller trades. While the 0.8% swap and DEX trading fee remains, removing the minimum fee lowers barriers for...
Nvidia's earnings report on Wednesday is the week's most anticipated event, with options pricing in a 6% share move due to factors like AI infrastructure demand, product ramp timing, China exposure, and new financing partnerships. Analysts warn of po...
Bitcoin surged over 20% in a single week, rising from around $62,700 to $79,500, marking one of its strongest weekly gains in recent years. This rally mirrors past major market reversals seen in 2019 and 2023, suggesting a possible new bull market cy...
Term Finance, a DeFi lending protocol on Ethereum, lost about $8.5 million after a hacker exploited its DAO governance system by buying a majority of governance tokens at low cost. This allowed the attacker to approve malicious proposals and drain 2,...
